- Home
- FNKO vs OCS Comparison
FNKO vs OCS Comparison
Compare FNKO & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNKO
- OCS
- Stock Information
- Founded
- FNKO 2017
- OCS 2003
- Country
- FNKO United States
- OCS Switzerland
- Employees
- FNKO N/A
- OCS N/A
- Industry
- FNKO Recreational Games/Products/Toys
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- FNKO Consumer Discretionary
- OCS Health Care
- Exchange
- FNKO Nasdaq
- OCS Nasdaq
- Market Cap
- FNKO 708.1M
- OCS 689.8M
- IPO Year
- FNKO 2017
- OCS N/A
- Fundamental
- Price
- FNKO $3.51
- OCS $18.58
- Analyst Decision
- FNKO Strong Buy
- OCS Strong Buy
- Analyst Count
- FNKO 3
- OCS 4
- Target Price
- FNKO $11.33
- OCS $31.50
- AVG Volume (30 Days)
- FNKO 1.0M
- OCS 28.3K
- Earning Date
- FNKO 05-08-2025
- OCS 05-08-2025
- Dividend Yield
- FNKO N/A
- OCS N/A
- EPS Growth
- FNKO N/A
- OCS N/A
- EPS
- FNKO N/A
- OCS N/A
- Revenue
- FNKO $1,024,890,000.00
- OCS $847,333.00
- Revenue This Year
- FNKO $3.25
- OCS $49.27
- Revenue Next Year
- FNKO $8.30
- OCS $1,920.31
- P/E Ratio
- FNKO N/A
- OCS N/A
- Revenue Growth
- FNKO N/A
- OCS N/A
- 52 Week Low
- FNKO $3.79
- OCS $10.79
- 52 Week High
- FNKO $14.65
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- FNKO 29.15
- OCS 54.68
- Support Level
- FNKO $3.79
- OCS $18.01
- Resistance Level
- FNKO $4.33
- OCS $19.50
- Average True Range (ATR)
- FNKO 0.28
- OCS 0.77
- MACD
- FNKO 0.14
- OCS 0.17
- Stochastic Oscillator
- FNKO 0.97
- OCS 66.30
About FNKO Funko Inc.
Funko Inc is an us-based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.